Navigation Links
Investigators Find Poisonous Chemicals In Four More Drugs In China

rch. Niu and six others at the drug maker, including three top company officials, have been detained.

The Hospital Affiliated to Sun Yat-sen University in Guangdong's provincial capital Guangzhou bought 3,600 ampoules of the tainted Armillarisin, the Guangzhou Daily reported yesterday. The hospital used 887 ampoules on its patients. The hospital authorities have said five people had died of kidney failure caused by the injections.

The police have placed seven suspects, including factory leaders, under arrest. The, police officers from Guangdong province arrived at the pharmaceutical factory for on-site investigations on Wednesday.

Meanwhile experts feel that a complete overhaul of China's drug production enforcement laws is necessary following the deaths of five people administered with counterfeit medication. While some were concerned with drug safety in hospitals, and others are condemning the drug maker, there is a general feeling about the ineffective drug inspection system in China at present, and a appeal for a fairer drug production and distribution environment in China. Many experts believe that China has been weak in imposing penalty measures on the producers of unqualified products, and appealed for stiffer penalties to be imposed.


'"/>




Page: 1 2

Related medicine news :

1. Poisonous Parkinsons molecule discovered
2. Poisonous Gas Caused Mass Extinction
3. Caution: Apricot Seeds May Be Poisonous
4. Hong Kong Citizens Fear over Poisonous Vegetables in Local Markets
5. Lakhs of Indians Exposed to High Levels of Poisonous Gases
6. Four of Family Died After Consuming Poisonous Mushrooms
7. Lead With a Poisonous Electron Shield
8. Chemicals in clear plastics can cause learning difficulties
9. Sedatives Derived From Chemicals Can Make Elderly Nervous
10. Chemicals causing Cancer Found In Soft Drinks In UK
11. Online Auction Results In Purchase of Chemicals
Post Your Comments:
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 1KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 2KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 4KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 5KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 6Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 1Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 2Alzheimers Soars Global Focus Needed 3A Study 57748 1Alzheimers Soars Global Focus Needed 3A Study 57748 2Alzheimers Soars Global Focus Needed 3A Study 57748 3
Other Medicine Technology:Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10